Surabhi Dangi-Garimella, PhD


Ibrutinib Could Enhance CAR T-Cell Treatment Impact in CLL

February 10th 2017

Treatment with concurrent ibrutinib improves expansion of chimeric antigen receptor T-cells and could subsequently improve response in patients with chronic lymphocytic leukemia, according to a study presented during the 2017 ASH Annual Meeting.

Study Identifies Potential Biomarkers for CAR T-Cell Therapy Response in CLL

February 10th 2017

A study presented at the 2016 ASH Annual Meeting identified potential biomarkers of response to anti-CD19 CAR T-cell treatment in patients diagnosed with chronic lymphocytic leukemia.

Upfront Ibrutinib Continues to Impress in CLL

February 3rd 2017

At 29 months’ follow-up, frontline ibrutinib reduced the risk of of progression or death by 88% versus chlorambucil in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma, according to the latest findings from the phase III RESONATE-2 trial.

Palbociclib Enhances Ibrutinib's Impact in MCL

December 27th 2016

Palbociclib can help patients with mantle cell lymphoma overcome resistance to ibrutinib, according to phase I results presented at the 2016 ASH Annual Meeting.

NCCN Readies Practitioners for Tapping the Potential of Biosimilars

April 1st 2016

While biosimilars have the potential to create competition and result in healthcare savings, the path to the marketplace has proven complex.

The Many Facets of Palliative Care Call for Team-Based Approach

March 31st 2016

The 2016 NCCN Annual Conference included a push to find more effective ways to encourage and deliver palliative care services across a variety of settings in oncology.

Bankruptcy in Cancer Survivors

February 13th 2016

Matthew Banegas, PhD, MPH, discusses a recent study that found that a considerable number of working-age adults who survive cancer and its toxic treatments, end up with substantial medical debts or declare bankruptcy.

Framing the Challenges of Next-Generation Sequencing

October 30th 2015

Bioinformatics research has developed rapid, increasingly specific, and cost-effective tools to analyze and interpret health information.

Playing Field Tilted Against Small Practices

October 9th 2015

Bruce J. Gould, MD, shares his experience as a private oncology practitioner facing competition from large medical centers with respect to 340B drug pricing.

Novel Agents Continue to Transform Lymphoma Treatment

July 27th 2015

Gilles A. Salles, MD, PhD, discussed treatment regimens being developed for follicular lymphoma.

Cardio-Oncology Program Puts Focus on Managing High-Risk Patients

July 8th 2015

Anju Nohria, MD, explains how the Cardio-Oncology Program originated and some of the challenges clinicians face in identifying high-risk patients and monitoring cardiovascular risks.

Many Challenges Loom in Ensuring Validity and Utility of Diagnostic Tests

May 12th 2015

While diagnostic tests play a critical role in physician decision making-particularly in oncology-questions remain regarding the clinical utility of some of these tests, as well as the validity of laboratory-developed tests.

Stem Cells Create a Therapeutic Niche

October 18th 2014

Stem cell therapy has gained increasing traction in various therapeutic areas, from cancer to diabetes to ocular regeneration.

USPSTF, ASCO Issue More Guidance on Genetic Testing Based on Family History

June 11th 2014

Oncology practitioners now have several resources to consult for advice on genetic testing for their patients following the US Preventive Services Task Force (USPSTF) December 2013 update of its 2005 BRCA recommendations.